1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. PRE-CLINICAL CRO MARKET BY SERVICE TYPE
5.1. Introduction
5.2. Toxicology Testing
5.3. Pharmacokinetics (PK) & Pharmacodynamics (PD)
5.4. Safety Pharmacology
5.5. Bioanalytical Services
5.6. In Vitro Testing
5.7. In Vivo Models
6. PRE-CLINICAL CRO MARKET BY DRUG TYPE
6.1. Introduction
6.2. Biologics
6.3. Vaccines
6.4. Small Molecules
6.5. Cell/Gene Therapies
7. PRE-CLINICAL CRO MARKET BY THERAPEUTIC AREA
7.1. Introduction
7.2. Oncology
7.3. CNS Disorders
7.4. Infectious Diseases
7.5. Cardiovascular Diseases
7.6. Metabolic Disorders
7.7. Rare Diseases
7.8. Others
8. PRE-CLINICAL CRO MARKET BY END-USER
8.1. Introduction
8.2. Biotech Startups
8.3. Large Pharma
8.4. Medical Device Companies
8.5. Academic/Government Institutes
9. PRE-CLINICAL CRO MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. By Service Type
9.2.2. By Drug Type
9.2.3. By Therapeutic Area
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. USA
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Service Type
9.3.2. By Drug Type
9.3.3. By Therapeutic Area
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Service Type
9.4.2. By Drug Type
9.4.3. By Therapeutic Area
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. United Kingdom
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Others
9.5. Middle East and Africa
9.5.1. By Service Type
9.5.2. By Drug Type
9.5.3. By Therapeutic Area
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. UAE
9.5.5.3. Others
9.6. Asia Pacific
9.6.1. By Service Type
9.6.2. By Drug Type
9.6.3. By Therapeutic Area
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. China
9.6.5.2. Japan
9.6.5.3. India
9.6.5.4. South Korea
9.6.5.5. Taiwan
9.6.5.6. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Thermo Fisher Scientific Inc. (PPD)
11.2. Covance -Laboratory Corporation of America Holdings
11.3. Parexel International Corporation
11.4. Charles River Laboratories International, Inc.
11.5. Medpace Holdings, Inc.
11.6. Eurofins Scientific SE
11.7. Crown Bioscience Inc.
11.8. InSilico Trials S.r.l.
11.9. Proscia Inc.
11.10. WuXi AppTec Co., Ltd.
11.11. Fortrea Holdings Inc.
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations